BioSpace News Archive

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced financial results for the first quarter ended March 31, 2022, and highlighted recent corporate accomplishments.

Societal CDMO, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, reported financial results for the first quarter ended March 31, 2022.

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2022 and provided a business update.

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced that company management will present and participate in one-on-one meetings at the following investor conferences in May.

LumiraDx Limited, a next-generation point of care diagnostics company, announced financial and operational results for the first quarter ended March 31, 2022.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2022 and provided a business update.

Intercept Pharmaceuticals, Inc. today announced the first patient has been dosed in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF).

Myeloid today announced the first patient dosed in the IMAGINE Study, a Phase 1/2 clinical study of MT-101, in patients with refractory or relapsed peripheral T cell lymphoma (PTCL), an aggressive form of non-Hodgkin lymphoma.

Stella Diagnostics, Inc. announced that its abstract titled “Markers in STLA101 Assay Detects Differential Expression to Distinguish Between Intramucosal and Invasive Esophageal Adenocarcinoma” has been selected for presentation during Digestive Disease Week 2022, which will take place May 21–24, 2022 at the San Diego Convention Center in San Diego, CA.

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS ® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis.